Can CKD Stage 3 Be Reversed?
True reversal of CKD stage 3 to normal kidney function is rare and not the realistic goal of treatment; however, improvement in kidney function (regression) and even remission can occur with aggressive, evidence-based therapy, particularly with the newer kidney-protective medications.
Understanding CKD Improvement vs. Reversal
While complete "reversal" to normal kidney function is uncommon, the concept of CKD regression and remission is now recognized 1. Regression is defined as a sustained increase in GFR by ≥25% with improvement in GFR category, while remission means achieving GFR ≥60 ml/min/1.73m² with urine albumin-to-creatinine ratio <30 mg/g 1.
The primary goal remains slowing progression and preventing complications, but improvement in kidney function is achievable in some patients.
Evidence for Kidney Function Improvement
Real-world data demonstrates that proper CKD management can significantly slow or even improve kidney function:
- In patients with diagnosed stage 3 CKD, annual eGFR decline was reduced from 3.20 ml/min/1.73m² before diagnosis to 0.74 ml/min/1.73m² after diagnosis when guideline-recommended therapies were implemented 2
- This improvement was associated with increased use of kidney-protective medications following formal CKD diagnosis 2
- Delayed diagnosis by even 1 year increases risk of progression to stage 4/5 CKD by 40% and kidney failure by 63% 2
Evidence-Based Treatment Strategy to Maximize Kidney Function
1. SGLT2 Inhibitors (First-Line Therapy)
For adults with CKD stage 3 and eGFR ≥20 ml/min/1.73m², SGLT2 inhibitors are now recommended as foundational therapy 3:
- Strong recommendation (1A) for patients with urine ACR ≥200 mg/g or heart failure 3
- Suggested (2B) even for those with ACR <200 mg/g if eGFR 20-45 ml/min/1.73m² 3
- Continue even if eGFR falls below 20 unless not tolerated 3
- The initial reversible decrease in eGFR after starting SGLT2i is not an indication to stop 3
2. RAS Inhibition (ACE Inhibitors or ARBs)
Use ACE inhibitors or ARBs for blood pressure control and proteinuria reduction 3, 4:
- Strong recommendation for hypertensive patients with stage 3 CKD 4
- Continue even when eGFR falls below 30 ml/min/1.73m² 3
- Accept up to 30% increase in creatinine after initiation 3
- Only reduce dose or discontinue for symptomatic hypotension or uncontrolled hyperkalemia 3
3. Nonsteroidal Mineralocorticoid Receptor Antagonists
For patients with type 2 diabetes, eGFR >25 ml/min/1.73m², and persistent albuminuria (>30 mg/g) despite maximum tolerated RASi, add finerenone 3:
- Suggested recommendation (2A) 3
- Can be combined with RASi and SGLT2i 3
- Requires careful potassium monitoring (initiate only if K+ ≤4.8 mmol/L) 3
4. Statin Therapy
Use statins for cardiovascular risk reduction in all stage 3 CKD patients with elevated LDL 4:
- Strong recommendation with moderate-quality evidence 4
Critical Pitfalls to Avoid
- Don't stop SGLT2i due to initial eGFR dip: The early decrease in eGFR is hemodynamic and reversible, not harmful 3
- Don't discontinue RASi prematurely: Continue even with eGFR <30 unless specific contraindications arise 3
- Don't delay diagnosis: Each year of delayed CKD diagnosis significantly worsens outcomes 2
- Don't withhold SGLT2i during sick days: Temporarily hold during prolonged fasting, surgery, or critical illness to prevent ketosis 3
Realistic Expectations
While experimental antifibrotic therapies show promise in reversing kidney fibrosis 5, 6, current clinical therapies primarily slow progression rather than restore normal kidney function. However, with optimal therapy combining SGLT2i, RASi, and appropriate adjunctive treatments, many patients can achieve stabilization or modest improvement in kidney function 2.
The most recent high-quality evidence (KDIGO 2024 guidelines) emphasizes that the combination of SGLT2 inhibitors with traditional RAS blockade represents the best current strategy to maximize kidney function preservation and potentially achieve regression in stage 3 CKD 3.